Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.

Enzyme map created by using a high-powered X-ray device.

Anasys Instruments Corp. has licensed a Department of Energy Oak Ridge National Laboratory technology that allows for simultaneous chemical and physical characterization and could lead to advances in materials and drug development.

Killian Award recipient Stephen Lippard describes his work on platinum-based chemotherapy agents

Chemists devise a new way to manufacture peptide drugs, which hold promise for treating many diseases.

As proof-of-principle, the team designs potent anti-cancer compound.

New recommendations for using X-rays promise to speed investigations aimed at understanding the structure and function of biologically important proteins – information critical to the development of new drugs. Scientists from two U.S. Department of Energy national laboratories, Argonne and Brookhaven, and the University of Washington, Seattle, evaluated options to remedy problems affecting data collection in their new study.

The probe mimics pathogen's amino acids, solving mystery behind Chlamydiae cell wall.